• Clinton J. Grubbs, Ph.D., is a basic scientist with a primary research interest in the chemoprevention of urinary bladder and mammary cancers. His major area of research is the identification of nutrient and non-nutrient agents that exhibit efficacy in the prevention of these cancers. He is a Professor in the UAB Department of Surgery and a Senior Scientist in the UAB Comprehensive Cancer Center. Dr. Grubbs received his doctoral degree from the University of Tennessee Medical Units in Memphis, Tennessee in 1973. He also completed a two year postdoctoral fellowship in biochemistry at the University of Tennessee Medical Unit. From 1975 to 1979, he was a senior physiologist at the Illinois Institute of Technology in Chicago, Illinois. After six years at Southern Research in Birmingham, he joined the faculty at UAB in the Department of Nutrition Sciences, and in 2000 transferred to the Department of Surgery. In 1987, he was awarded Master Agreements from the NCI for in vivo screening of chemopreventive agents and for the evaluation of the efficacy of potential preventive compounds. The agreements, now a Prime Contractor, continue to be active. Through this funding, Dr. Grubbs has established subcontracts for chemoprevention research with five universities and research institutes in the United States. Dr. Grubbs has established a national and international reputation in the preclinical evaluation of chemopreventive agents in cancer. His research is published in widely read peer-reviewed journals. At UAB, he served as Chair of the UAB IACUC Committee from 1987-2001. He also served on the PREVENT Review Panel of the National Cancer Institute for more than 10 years.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 [Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.Oncology Reports.  41:718. 2019
    2018 Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.Cancer Prevention Research.  11:595-606. 2018
    2018 Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.Oncology Reports.  40:1545-1553. 2018
    2018 A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.Journal of Surgical Research.  228:54-62. 2018
    2018 The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.Journal of Dermatological Science.  90:343-356. 2018
    2017 Erratum to: Mass spectrometric evidence for the modification of small molecules in a cobalt-60-irradiated rodent diet: Irradiation modifies the content of animal diet (Journal of Mass Spectrometry, (2017), 52, 8, (507-516), 10.1002/jms.3950)Journal of Mass Spectrometry.  52:707. 2017
    2017 Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.Oncology Letters.  14:3480-3486. 2017
    2017 Mass spectrometric evidence for the modification of small molecules in a cobalt-60-irradiated rodent diet.Journal of Mass Spectrometry.  52:507-516. 2017
    2017 Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.Current Topics in Medicinal Chemistry.  17:676-695. 2017
    2016 5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?Cancer Prevention Research.  9:616-623. 2016
    2016 Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.Molecular Cancer Therapeutics.  15:911-921. 2016
    2015 Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.Journal of Medicinal Chemistry.  58:7763-7774. 2015
    2015 Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.Molecular Cancer Therapeutics.  14:1559-1569. 2015
    2015 Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.Cancer Prevention Research.  8:296-302. 2015
    2015 Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.Cancer Prevention Research.  8:231-239. 2015
    2014 Global molecular changes in rat livers treated with RXR agonists: a comparison using transcriptomics and proteomicsPharmacology Research and Perspectives.  2. 2014
    2014 Effect of Withania somnifera root extract on spontaneous estrogen receptor-negative mammary cancer in MMTV/Neu mice.Anticancer Research.  34:6327-6332. 2014
    2014 Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.Journal of Medicinal Chemistry.  57:5370-5380. 2014
    2014 Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.Cancer Prevention Research.  7:236-245. 2014
    2014 Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.Cancer Prevention Research.  7:246-254. 2014
    2014 Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.Bioorganic and Medicinal Chemistry.  22:178-185. 2014
    2013 Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.Cancer Prevention Research.  6:1151-1161. 2013
    2013 Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.Cancer Prevention Research.  6:448-454. 2013
    2013 Effect of an extract of Withania somnifera root on estrogen receptor-positive mammary carcinomas.Anticancer Research.  33:1519-1523. 2013
    2013 Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).Molecular Pharmacology.  83:698-708. 2013
    2013 Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis.Molecular Carcinogenesis.  52:134-143. 2013
    2013 Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model.PLoS ONE.  8:e64445. 2013
    2012 The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.Cancer Prevention Research.  5:810-821. 2012
    2012 Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.Oncology Reports.  27:1400-1406. 2012
    2012 Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.Cancer Prevention Research.  5:248-259. 2012
    2011 Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?Oncology Reports.  26:731-736. 2011
    2011 Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.Cancer Prevention Research.  4:1190-1197. 2011
    2011 Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity.Nahrung..  55:1249-1265. 2011
    2011 Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.Oncology Reports.  25:1389-1397. 2011
    2010 A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.Cancer Prevention Research.  3:1565-1570. 2010
    2010 Parity is associated with an expanded macrophage population in the mammary gland.International Journal of Oncology.  37:1195-1202. 2010
    2010 Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.American Journal of Translational Research.  3:8-27. 2010
    2010 Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.Journal of Urology, The.  183:1598-1603. 2010
    2009 Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element.Chemico-Biological Interactions.  182:22-28. 2009
    2009 Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.Cancer Prevention Research.  2:951-956. 2009
    2009 High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.International Journal of Oncology.  34:1425-1431. 2009
    2009 Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.Cancer Prevention Research.  2:161-167. 2009
    2009 Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoidCancer Biology and Therapy.  8:285-294. 2009
    2009 Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.Cancer Biology and Therapy.  8:289-298. 2009
    2008 Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.International Journal of Cancer.  123:2254-2259. 2008
    2008 Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers.Oncology Reports.  19:1565-1570. 2008
    2008 Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.Molecular Cancer Therapeutics.  7:972-979. 2008
    2007 Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.Clinical Cancer Research.  13:5488-5496. 2007
    2007 Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols.Molecular Cancer Therapeutics.  6:2022-2028. 2007
    2007 Gene expression profiling of chemically induced rat bladder tumors.Neoplasia : An International Journal for Oncology Research.  9:207-221. 2007
    2006 Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.Carcinogenesis.  27:1420-1431. 2006
    2006 Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.Carcinogenesis.  27:1232-1239. 2006
    2006 Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.Molecular Cancer Therapeutics.  5:1073-1078. 2006
    2006 Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide.Molecular Cancer Therapeutics.  5:1060-1072. 2006
    2005 Hypermethylation patterns in the Fhit regulatory region are tissue specific.Molecular Carcinogenesis.  43:175-181. 2005
    2005 Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.Oncogene.  24:3554-3562. 2005
    2005 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin.Carcinogenesis.  26:571-578. 2005
    2005 Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.Carcinogenesis.  26:441-448. 2005
    2004 Proteomics analysis of rat brain protein modulations by grape seed extract.Journal of Agricultural and Food Chemistry.  52:7872-7883. 2004
    2004 Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine.Neoplasia : An International Journal for Oncology Research.  6:569-577. 2004
    2004 CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors.Oncogene.  23:3990-3998. 2004
    2004 Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models.Oncogene.  23:3841-3850. 2004
    2004 Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention.Oncology Reports.  11:465-469. 2004
    2003 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.Cancer Letters.  201:17-24. 2003
    2003 Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30).Journal of Medicinal Chemistry.  46:3766-3769. 2003
    2003 Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity.Oncogene.  22:2568-2572. 2003
    2003 Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors.Breast Cancer Research and Treatment.  77:253-264. 2003
    2003 The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial.Cancer Epidemiology, Biomarkers and Prevention.  12:114-119. 2003
    2002 Multiple comparisons model-based clustering and ternary pattern tree numerical display of gene response to treatment: procedure and application to the preclinical evaluation of chemopreventive agents.Molecular Cancer Therapeutics.  1:1283-1292. 2002
    2002 Paradigms for primary prevention of ovarian carcinoma.CA: A Cancer Journal for Clinicians.  52:216-225. 2002
    2002 Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3.Oncology Reports.  9:533-537. 2002
    2002 Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology.Nutrition and Cancer.  43:67-75. 2002
    2001 Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitorOncogene.  20:7710-7721. 2001
    2001 Effect of high retinoid doses on RAR-β mRNA expression in female B6D2F1 miceAnticancer Research.  21:1691-1695. 2001
    2001 Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.Cancer Research.  61:3961-3968. 2001
    2001 Differences in plasma and nipple aspirate carotenoid by lactation status.Nursing Research.  50:172-177. 2001
    2001 Modulation of biomarkers by chemopreventive agents in smoke-exposed rats.Cancer Research.  61:2472-2479. 2001
    2001 Presence of carotenoid, an anticarcinogenic marker, in nipple aspirates postlactation.Advances in Experimental Medicine and Biology.  501:143-152. 2001
    2001 Therapeutic and chemopreventive effects of R115777, a farnesyl transferase inhibitor (FTI), on methylnitrosourea (MNU)-induced rat mammary cancerBreast Cancer Research and Treatment.  69:216. 2001
    2000 Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.Cancer Research.  60:5599-5602. 2000
    2000 Longitudinal analysis of mammary cancer multiplicity in chemoprevention studies.Anticancer Research.  20:2281-2287. 2000
    2000 Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.Breast Cancer Research and Treatment.  60:117-128. 2000
    2000 Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat.Proceedings of the Society for Experimental Biology and Medicine.  223:288-294. 2000
    1999 Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents.Cancer Research.  59:4285-4290. 1999
    1999 Protective effects of estrogen in a rat model of age-related cataracts.Proceedings of the National Academy of Sciences.  96:9328-9332. 1999
    1999 A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors.Molecular Carcinogenesis.  24:47-56. 1999
    1999 Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.Carcinogenesis.  20:71-76. 1999
    1998 Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.Carcinogenesis.  19:1345-1351. 1998
    1998 Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosourea.Oncology Reports.  5:857-860. 1998
    1998 Retinyl substituted-benzyl ethers. Inhibition of mammary carcinogenesis by retinyl 3,4,5-trimethoxybenzyl ether (RTMBE).Anticancer Drug Design.  13:159-182. 1998
    1998 Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.Cancer Research.  58:921-926. 1998
    1997 Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancerAnticancer Research.  17:4639-4645. 1997
    1997 Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model.International Journal of Cancer.  72:95-101. 1997
    1997 Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer.Anticancer Drug Design.  12:15-33. 1997
    1996 Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.Carcinogenesis.  17:1305-1311. 1996
    1995 Effects of dehydroepiandrosterone on MNU-induced breast cancer in Sprague-Dawley rats.Annals of the New York Academy of Sciences.  774:340-341. 1995
    1995 Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol.Anticancer Research.  15:709-716. 1995
    1994 Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.Carcinogenesis.  15:2775-2780. 1994
    1994 Potential role of dietary isoflavones in the prevention of cancer.Advances in Experimental Medicine and Biology.  354:135-147. 1994
    1994 Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.Journal of Cellular Biochemistry -Supplement-.  20:32-54. 1994
    1993 Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors.Anticancer Research.  13:33-36. 1993
    1993 The statistical analysis of cancer inhibition/promotion experimentsAnticancer Research.  13:1357-1363. 1993
    1992 Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors.JNCI: Journal of the National Cancer Institute.  84:1740-1744. 1992
    1992 Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.Biochemical Journal.  283 ( Pt 1):209-216. 1992
    1992 Retinoids and cancer prevention.Annual Review of Nutrition.  12:161-181. 1992
    1991 Effect of canthaxanthin on chemically induced mammary carcinogenesis.Oncology.  48:239-245. 1991
    1990 Effect of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumors.Anticancer Research.  10:661-666. 1990
    1990 Effect of miso (Japanese soybean paste) and NaCl on DMBA-induced rat mammary tumors.Nutrition and Cancer.  14:103-109. 1990
    1990 Soybeans inhibit mammary tumors in models of breast cancer.Progress in clinical and biological research.  347:239-253. 1990
    1988 Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats.Anticancer Research.  8:113-117. 1988
    1986 Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland.Anticancer Research.  6:1395-1400. 1986
    1985 Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone.JNCI: Journal of the National Cancer Institute.  74:927-931. 1985
    1985 Effect of long-term administration of retinoids on rats exposed transplacentally to ethylnitrosourea.Anticancer Research.  5:205-209. 1985
    1985 Intestinal absorption of nutrients in animals dosed orally with retinoids: considerations for chemopreventive studies.Cancer Investigation.  3:243-248. 1985
    1985 Suppression of methylnitrosourea (MNU)-induced mammary cancers by pregnancy: Elimination of preneoplastic cellsProceedings of the American Association for Cancer Research.  VOL. 26. 1985
    1983 N-nitroso-N-methylurea-induced mammary carcinogenesis: effect of pregnancy on preneoplastic cells.JNCI: Journal of the National Cancer Institute.  71:625-628. 1983
    1983 Effect of ovarian hormones on the induction of 1-methyl-1-nitrosourea-induced mammary cancer.Carcinogenesis.  4:495-497. 1983
    1983 Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration.JNCI: Journal of the National Cancer Institute.  70:209-212. 1983
    1982 Effect of age at time of 1-methyl-1-nitrosourea administration on mammary carcinogenesisProceedings of the American Association for Cancer Research.  Vol. 23. 1982
    1982 Retinoids as chemopreventive and anticancer agents intact animals (review).Anticancer Research.  2:111-124. 1982
    1981 Carcinogenicity of N-methyl-N-nitrosourea and N-ethyl-N-nitrosourea when applied to a localized area of the hamster trachea.JNCI: Journal of the National Cancer Institute.  66:961-965. 1981
    1981 Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice.Cancer Research.  41:933-936. 1981
    1980 Histogenesis and dose dependence of N-methyl-N-nitrosourea-induced carcinoma in a localized area of the hamster trachea.JNCI: Journal of the National Cancer Institute.  64:1135-1140. 1980
    1979 Photooxidation products of 7,12-dimethylbenz[a]anthracene.Chemico-Biological Interactions.  26:339-347. 1979
    1979 N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.Cancer Research.  39:1339-1346. 1979
    1979 1-methyl-1-nitrosourea induction of cancer in a localized area of the Syrian golden hamster trachea.Progress in Experimental Tumor Research.  24:345-355. 1979
    1979 A quantitative dosing schedule for the induction of transitional cell carcinomas in female F344 rats with the use of N-butyl-N-(4-hydroxybutyl)nitrosamine.JNCI: Journal of the National Cancer Institute.  62:187-191. 1979
    1979 Comparison of tumor induction by ethylnitrosourea and methylnitrosourea in a localized lung tumor modelProceedings of the American Association for Cancer Research.  Vol. 20:389. 1979
    1978 Effect of retinoids on N-methyl-N-nitrosourea (MNU)-induced mammary cancerFederation proceedings.  37. 1978
    1978 Hepatic lipocytes and storage of vitamin A analoguesFederation proceedings.  37. 1978
    1978 Induction of transitional cell carcinomas (TCC) with N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) in female ratsProceedings of the American Association for Cancer Research.  Vol. 19. 1978
    1978 N-methyl-N-nitrosourea (MNU)-induction of tracheal cancer. A respiratory cancer model with short latency periodFederation proceedings.  37. 1978
    1977 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.Science.  198:743-744. 1977
    1977 Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea.Nature.  267:620-621. 1977
    1977 Inhibition of mammary cancer by retinyl methyl ether.Cancer Research.  37:599-602. 1977
    1977 Suppression of NMU induced mammary cancer by vitamin A acetateProceedings of the American Association for Cancer Research.  Vol.18. 1977
    1976 Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis by retinyl acetate.Cancer Research.  36:2626-2630. 1976
    1976 The binding of benz(a)anthracene derivatives to glyceraldehyde-3-phosphate dehydrogenase and mammary tissue following exposure to laboratory light.Chemico-Biological Interactions.  12:135-144. 1976
    1976 Suppression of DMBA induced mammary tumorigenesis by retinyl methyl etherProceedings of the American Association for Cancer Research.  Vol. 17. 1976
    1975 The inhibition of glyceradehyde-3-phosphate dehydrogenase by benz(a)anthracene and its derivatives after exposure to laboratory lighting.Chemico-Biological Interactions.  10:173-183. 1975
    1975 Effect of age and parity upon the uptake of 9,10-dimethyl-1,2-benzanthracene-9-14C by mammary parenchymal cells of the rat.British Journal of Cancer.  31:189-196. 1975
    1975 Binding of light exposed benz(a)anthracene (BA) derivatives to glyceraldehyde 3 phosphate dehydrogenase (GPDH) and mammary tissueProceedings of the American Association for Cancer Research.  16. 1975
    1974 Uptake of progesterone-14C and estradiol-3H by isolated normal mammary parenchymal and cancer cells of the rat.European Journal of Cancer.  10:707-712. 1974
    1974 Effect of light on the reaction of glyceraldehyde 3 phosphate dehydrogenase with DMBA derivativesProceedings of the American Association for Cancer Research.  Vol. 15:53. 1974
    1973 Transport of orally administered 9,10-dimethyl-1,2-benzanthracene in the Sprague-Dawley rat.Cancer Research.  33:1785-1789. 1973
    1973 Uptake of estradiol 6,73H by isolated rat mammary parenchymal and tumor cells in vivo and in vitroFederation proceedings.  32:3419. 1973

    Principal Investigator On

  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T001 HHSN2610001 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Kick Off Meeting - Contract Orientation and Kick Off Meeting  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T002 HHSN2610002 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-02 - Evaluation of Agents/Protocols that Inhibity the Two Major Pathways Involved in Human Urinary Bladder Cancer [PI3K, EGFR] and Protocols to Reduce their Toxicity  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T003 HHSN2610003 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-07 - Evaluation of the Cancer Prevention Efficacy of GLG-302  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T004 HHSN2610004 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Immunologic Effects of NSAIDs With and Without a Vaccine in Colon Cancer Prevention  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T005 HHSN26100005 TORFP 2017-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluation of "Clinical-Ready" Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T007 HHSN26100007 TORRP-EZ-2018-E01 Evaluation of STAT-3 ANtagonists in the Prevention of Mammary Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T008 HHSN26100009 TORFP 2018-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of HER2-IGFPB2-IGFLR Vaccine in Eliminating Existing Ductal Carcinoma in Situ and Preventing Progression of Invasive Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T009 HHSN26100008 TORFP 2018-E03 Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) when Administered in Combination  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T010 HHSN26100010 TORFP 2018-E07 Preclinical Development of a Chemopreventive Agent, 4-Methylumbelliferone (4-MU)  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T011 HHSN26100011 TORFP 2018-E08 Further Development of Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Contract Orientation Meeting with NCI, Office of Acquistions  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100002 Efficacacy of a Multi-Antegen Vaccine in the Prevention of MethyInitrosourea-Introduced Mammary Cancers (ER+) in Female Sprague-Dawley Rats  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100003 Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventative Agents Employing Both High Risk (But Histologically Normally) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100004 TORFP IV/IV 2013-3 Evaluation of GLG-302, a STAT3 Antagonist in the Prevention of Mammary Cancer  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100005 TORFP IV/IV 2013-4 Efficacy of Metformin in the Methylnitrosourea-Induced Model EF+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100006 TORFP 2014-3I Evaluation of the Prevention by Actoplus/Met (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancer Occurring in Rodents on a High-Fat Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100007 TORFP 2014-5I Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Preclinical in Vitro and In Vivo Agent Development Assays  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Preclinical In Vitro and In Vivo Screening Assays for Cancer Preventive Agent Development  awarded by National Cancer Institute/NIH/DHHS 2004 - 2012
  • Private Grant  awarded by FISHER BIOSERVICES 2009 - 2011
  • OH-BBN Induced Rat Bladder Tumors: Comparative Efficacy of Sulindac, NO-Sulindac and DFMO  awarded by University of Michigan 2008 - 2011
  • Investigator On

  • RXR Rexinoids for Cancer Chemoprevention  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • RXR Rexinoids for Cancer Chemoprevention - Core 3: Rexinoid Screening and Animal Core  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Comprehensive Cancer Center Core Support Grant - Cancer Chemoprevention Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Chemoprevention of Breast Cancer with Rexinoids that Inhibit Obesity-Induced Metabolic Syndrome  awarded by National Cancer Institute/NIH/DHHS 2016 - 2019
  • Preclinical in Vitro and In Vivo Agent Development Assays  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Cancer Chemoprevention Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Education And Training

  • Doctor of Philosophy, University of Memphis
  • Master of Arts, University of Memphis
  • Full Name

  • Clinton Grubbs
  • Blazerid

  • horses